ArrowMark Colorado Holdings LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS)

ArrowMark Colorado Holdings LLC grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 439,487 shares of the medical research company's stock after buying an additional 19,528 shares during the period. ArrowMark Colorado Holdings LLC owned 0.24% of Exact Sciences worth $24,695,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tidal Investments LLC boosted its position in shares of Exact Sciences by 172.2% during the 3rd quarter. Tidal Investments LLC now owns 34,275 shares of the medical research company's stock valued at $2,335,000 after acquiring an additional 21,683 shares during the last quarter. Synovus Financial Corp bought a new stake in Exact Sciences during the third quarter valued at approximately $490,000. GAMMA Investing LLC grew its stake in Exact Sciences by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock worth $206,000 after buying an additional 828 shares in the last quarter. Modus Advisors LLC bought a new position in shares of Exact Sciences in the 4th quarter worth $43,000. Finally, Everence Capital Management Inc. purchased a new stake in shares of Exact Sciences during the 4th quarter valued at $356,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EXAS has been the topic of a number of research reports. Barclays raised their price objective on Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a report on Friday. Mizuho initiated coverage on shares of Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective for the company. Benchmark reaffirmed a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Guggenheim restated a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Finally, Bank of America reduced their price objective on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.90.

Exact Sciences Trading Up 1.4 %

NASDAQ EXAS traded up $0.73 during trading hours on Tuesday, reaching $54.06. The company had a trading volume of 4,314,658 shares, compared to its average volume of 2,649,735. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $10.19 billion, a P/E ratio of -9.70 and a beta of 0.92. The stock has a 50-day moving average of $45.11 and a 200 day moving average of $53.07. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.16. The company had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Exact Sciences's revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.60) EPS. As a group, research analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.